HRH3 and obesity disorder: Pitolisant (Fig. 1) is an antagonist/inverse agonist at the H3 histamine receptor (EC50 (human H3 receptor) = 1.5 nM) (EMA 2015) and might reduce body weight and metabolic disturbances and be beneficial in the treatment of obesity.